美股新聞 標題聯播 · 近 24 小時 283 則 · 25 個來源 · 最新 9/20 07:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · DSGN近 30 天 0 則 · 第 1 / 1 頁
- Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
- Fuchs Endothelial Corneal Dystrophy Market Forecast Highlights Significant Growth During the Forecast Period (2026-2036), Owing to the Expanding Treatment Landscape and Increasing Patient Pool | DelveInsight
- Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
- Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
- Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
- This Biotech Leader Ran Up As Much As 18% — And Then Lost It All
- Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
- Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
- Design Therapeutics Inc (DSGN) Q1 2026 Earnings Call Highlights: Promising Progress in ...
- Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates
- We Think Design Therapeutics (NASDAQ:DSGN) Can Afford To Drive Business Growth
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。